Interim data for Merck’s MK-3475, an investigational Anti-PD-1 immunotherapy, in previously treated patients with non-small cell Lung Cancer to be presented at 15th World Conference on lung cancer
1 October 2013 | By Merck
An abstract (# 2416) published today summarized preliminary findings from 38 patients with NSCLC treated with MK-3475...